DR. REDDY'S GAMBIT

Frequent drug industry nemesis seeks to boost its custom manufacturing business

WHEN INDIA'S DR. REDDY'S Laboratories spent $59 million to buy a Mexican pharmaceutical chemical plant from Roche last November, the Indian firm said the move was part of a strategy to expand its custom pharmaceutical chemical business 10-fold. To achieve the target, Dr. Reddy's will also have to convince customers to look past the fact that it is also their legal nemesis.

Dr. Reddy's is the Indian generic drug producer that most often challenges larger pharmaceutical companies' patents in U.S. courts to gain market access. In the past few years, Reddy's has gone after the patents of Pfizer, GlaxoSmithKline, Eli Lilly & Co., Novartis, and other companies.

Abhijit Mukherjee, a seasoned executive who previously worked at leading consumer goods company Hindustan Lever, is Reddy's president of developing businesses and the person in charge of building up the custom pharmaceutical chemical business. He acknowledges that some potential customers will have a problem turning to Reddy's for their pharmaceutical chemical needs. "But if you look at it rationally, rather than in an emotional way, you'll seriously consider us," he says. "We offer excellence of service."

Mukherjee explains that Reddy's is a sophisticated company. One of India's top pharmaceutical firms, it has a great deal of manufacturing strength; it is ranked as the seventh best employer in India; and, partly because of its experience with legal challenges, has a deep understanding of drug regulations in the U.S. He adds that intellectual property is well-protected at Reddy's. "In the small world of custom pharmaceuticals, you violate your customer's IP only once. Your business is destroyed after that," he says.

Mukund S. Chorghade, a consultant who specializes in helping U.S. drug companies sourcing products and services from India, says it will be difficult for pharmaceutical companies to have anything other than an "emotional response" to Reddy's sales pitch. As a result, Chorghade anticipates that Reddy's will be relegated to supplying less complex pharmaceutical ingredients than are supplied by firms that do not challenge patents.

However, large drug companies are increasingly familiar with India, and this will work in Dr. Reddy's favor, Chorghade adds. "Five years ago, Pfizer did not outsource anything to India. Now, Pfizer is the leader in sourcing clinical trials and data management in India." He further notes that Wyeth recently signed a major chemistry outsourcing deal with GVK Bio (C&EN, Jan. 23, page 23).

Mukherjee says pharmaceutical custom manufacturing is a growth business. Large drug companies are outsourcing manufacturing to reduce costs and focus on other things that they consider their core activities. Reddy's launched its own chemical pharmaceutical business about three years ago to take advantage of this trend. The acquisition of the Roche plant increased the firm's custom pharmaceutical sales manyfold, he says, adding that he cannot provide exact numbers as it might affect Dr. Reddy's stock price.

Reddy's paid a premium for the Roche plant, Mukherjee says, because the sale included the plant's customers. He explains that it's normally cheaper for a company to establish a customer base through its own efforts, but the Roche deal presented a compelling opportunity to achieve critical mass. Mukherjee adds that it's unlikely customers of the Mexican plant will now look for another supplier because it would be too time-consuming and costly.

Following this acquisition, Dr. Reddy's will now refocus its attention on "organic growth" by signing up new customers and earning their trust. Building trust takes time, Mukherjee says. For now, "the basis of the relationship is spelled out in the contract," he says. Most customers were initially small biotech firms, but increasingly, large pharmaceutical companies are signing up.

He expects that customers will eventually be delighted by the quality of service from Reddy's. In this regard, the company's knowledge of U.S. pharmaceutical regulations is a strong asset, Mukherjee says. "If our knowledge of pharmaceutical filing regulations in the U.S. can save customers eight months, should they really care that we acquired this know-how from our generics business?"—JEAN-FRANÇOIS TREMBLAY

GLOBAL COMPETITOR Business is growing at Dr. Reddy's custom manufacturing plants. Shown here is a facility in Hyderabad.

2006 CU-Roche Colorado Symposium

The 2006 University of Colorado-Roche Colorado Symposium on Synthetic Organic Chemistry will be held June 7-9 at the University of Colorado. The Symposium features lectures on a wide range of topics in organic synthesis from a superb lineup of distinguished speakers from academia and the pharmaceutical industry.

- Professor Phil Baran, Scripps Research Institute
- Professor Justin D. Bois, Stanford University
- Professor Tohru Fukuyama, University of Tokyo
- Professor Stephen Kent, University of Chicago
- Professor Bruce Lu, Boehringer Ingelheim
- Dr. Bruce Maryanoff, Johnson & Johnson
- Dr. David Myles, Kansan Biosciences
- Professor Andy Phillips, University of Colorado
- Professor Paul Wender, Stanford University

We would like to invite you to join us at what has become a biennial tradition in Colorado, with over 250 attendees from across the US and from abroad. For more information see: www.colorado.edu/chemistry/Roche or write to Rosemary Trujillo, Department of Chemistry & Biochemistry, 215 UCB, Boulder, CO 80309-0215, or email rosemary.trujillo@colorado.edu.

Request more at AdInfoNow.org